Howard Berman is the CEO and co-founder of Coya Therapeutics, a Houston biotech company focused on Alzheimer's and other neurodegenerative diseases.
But when Berman's father was diagnosed with dementia, he was moved to action.
"I was interested in what I could do for my dad," Berman tells the Houston Innovators podcast.
So Berman teamed up with Stanley Appel, a neurologist at Houston Methodist Research Institute, to work on Alzheimer's and other neurodegenerative diseases.
Appel was able to stop the progression of ALS, also known as Lou Gehrig's disease, with one of Berman's treatments.
Now, Berman says, he's working on treatments for other neurodegenerative diseases, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, or ALS, which is also known as Lou Gehrig's disease.
Coya's lead treatment is a drug-eluting balloon that's currently in a clinical trial for Alzheimer's and other neurodegenerative diseases.
But it could also be used to treat other neurodegenerative diseases, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, or ALS, which is also known as Lou Gehrig's disease, the Houston Chronicle reports.
Berman's father died of
A customized collection of grant news from foundations and the federal government from around the Web.
A Gilesgate-based shop and community facility, Hexham’s Core Music, launches a separate workshop where up to six people will be trained how to repair guitars and make ukuleles. The European Social Fund grant supported the project and has secured funds through the County Durham Communication Foundation to equip the workshop in Burn Lane.